公开(公告)号：US12059416B2

公开(公告)日：2024-08-13

申请号：US17456617

申请日：2021-11-26

申请人： BIOPROJET

发明人： Xavier Ligneau ,  Laurent Landais ,  David Perrin ,  Jeanne Marie Lecomte ,  Jean Charles Schwartz

IPC分类号： A61K31/4545 ,  A61K31/381 ,  A61K31/4453 ,  A61P25/26

CPC分类号： A61K31/4545 ,  A61K31/381 ,  A61K31/4453 ,  A61P25/26

摘要： Disclosed are combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake promoting activity.

公开(公告)号：US20240174605A1

公开(公告)日：2024-05-30

申请号：US18279985

申请日：2022-03-01

申请人： RESEARCH TRIANGLE INSTITUTE

发明人： Yanan ZHANG ,  Dehui ZHANG

IPC分类号： C07C311/37 ,  A61K31/167 ,  A61K31/18 ,  A61K31/381 ,  A61K31/40 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/496 ,  A61P25/28 ,  C07C237/42 ,  C07D213/40 ,  C07D213/75 ,  C07D213/76 ,  C07D213/81 ,  C07D213/82 ,  C07D277/56 ,  C07D295/16 ,  C07D333/38 ,  C07D401/12 ,  C07D417/12

CPC分类号： C07C311/37 ,  A61K31/167 ,  A61K31/18 ,  A61K31/381 ,  A61K31/40 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/496 ,  A61P25/28 ,  C07C237/42 ,  C07D213/40 ,  C07D213/75 ,  C07D213/76 ,  C07D213/81 ,  C07D213/82 ,  C07D277/56 ,  C07D295/16 ,  C07D333/38 ,  C07D401/12 ,  C07D417/12 ,  C07C2601/02

摘要： The present disclosure provides novel arylsulfonamide compounds as embodiments of the present disclosure. The compounds are believed to be orexin receptor agonists, useful for the treatment of diseases and conditions caused by reduced activity of orexin.

公开(公告)号：US20240156770A1

公开(公告)日：2024-05-16

申请号：US18488616

申请日：2023-10-17

申请人： TECHFIELDS PHARMA CO., LTD.

发明人： Chongxi Yu

IPC分类号： A61K31/215 ,  A61K31/21 ,  A61K31/216 ,  A61K31/221 ,  A61K31/4453 ,  A61K47/54 ,  C07C219/10 ,  G01N33/50

CPC分类号： A61K31/215 ,  A61K31/21 ,  A61K31/216 ,  A61K31/221 ,  A61K31/4453 ,  A61K47/54 ,  C07C219/10 ,  G01N33/502 ,  C07C2601/16 ,  C07C2602/10

摘要： The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

公开(公告)号：US20240075147A1

公开(公告)日：2024-03-07

申请号：US18487486

申请日：2023-10-16

申请人： TRx Biosciences Limited

发明人： John Brew ,  Daniel Gooding ,  Robin M. Bannister

IPC分类号： A61K47/14 ,  A61K31/05 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/58 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/28

CPC分类号： A61K47/14 ,  A61K31/05 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/58 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/28

摘要： The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

公开(公告)号：US20240050423A1

公开(公告)日：2024-02-15

申请号：US18489863

申请日：2023-10-19

申请人： Prilenia Neurotherapeutics Ltd.

发明人： Michael HAYDEN ,  Mahmoud Abdulhossein Pouladi

IPC分类号： A61K31/4453 ,  A61K9/00 ,  A61P25/22 ,  A61K9/48 ,  A61P25/24

CPC分类号： A61K31/4453 ,  A61K9/0053 ,  A61P25/22 ,  A61K9/48 ,  A61P25/24

摘要： The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject.

公开(公告)号：US20190209575A1

公开(公告)日：2019-07-11

申请号：US16360375

申请日：2019-03-21

申请人： MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA ,  SEMMELWEIS EGYETEM ,  SigmaDrugs Kft.

发明人： Andrea Fekete ,  Ádám Vannay ,  Endre Illés Kovács

IPC分类号： A61K31/5375 ,  A61K31/4985 ,  A61K31/495 ,  A61K31/4515 ,  A61K31/4468 ,  A61K31/4453 ,  A61K31/135 ,  A61K31/341 ,  A61K31/215 ,  A61K31/15 ,  A61K31/138 ,  A61K31/402

CPC分类号： A61K31/5375 ,  A61K31/135 ,  A61K31/138 ,  A61K31/15 ,  A61K31/215 ,  A61K31/341 ,  A61K31/402 ,  A61K31/4453 ,  A61K31/4468 ,  A61K31/4515 ,  A61K31/495 ,  A61K31/4985

摘要： Compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. Embodiments relate to the use of Sigma-1 receptor agonists for use in the treatment of prevention of progressive fibrosis characterized by the over proliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1 agonists are disclosed.

公开(公告)号：US20190185820A1

公开(公告)日：2019-06-20

申请号：US16319749

申请日：2017-08-23

申请人： The Regents of the University of California

发明人： Danica Chen ,  Hanzhi Luo

IPC分类号： C12N5/16 ,  C12N15/85 ,  C12N15/113 ,  A61K35/28 ,  C12N5/074 ,  A61P25/28 ,  A61P21/00 ,  A61K31/7105 ,  A61K31/4453

CPC分类号： C12N5/16 ,  A61K31/4453 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K35/28 ,  A61K45/06 ,  A61P21/00 ,  A61P25/28 ,  C12N5/0607 ,  C12N5/0647 ,  C12N15/1137 ,  C12N15/85 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2330/50 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2510/00

摘要： The present disclosure provides methods of improving the function of stem cells, and/or reducing or inhibiting or inhibiting stem cell aging.

公开(公告)号：US20180318380A1

公开(公告)日：2018-11-08

申请号：US16019194

申请日：2018-06-26

申请人： BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA

发明人： Dean Burkin ,  Ryan Wuebbles

IPC分类号： A61K38/05 ,  A61K45/06 ,  A61K31/16 ,  A61K31/661 ,  A61K31/575 ,  A61K31/57 ,  A61K31/551 ,  A61K31/541 ,  A61K31/5383 ,  A61K31/5377 ,  A61K31/5375 ,  A61K31/5365 ,  A61K31/53 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4985 ,  A61K31/498 ,  A61K31/496 ,  A61K31/473 ,  A61K31/4709 ,  A61K31/47 ,  A61K31/444 ,  A61K31/4418 ,  A61K31/4402 ,  A61K31/4365 ,  A61K31/426 ,  A61K31/421 ,  A61K31/4196 ,  A61K31/4178 ,  A61K38/39 ,  A61K31/19 ,  A61K31/415 ,  A61K31/41 ,  A61K31/4035 ,  A61K31/4025 ,  A61K31/381 ,  A61K31/37 ,  A61K31/36 ,  A61K31/343 ,  A61K31/341 ,  A61K31/277 ,  A61K31/20 ,  A61K31/404 ,  A61K31/4164

CPC分类号： A61K38/05 ,  A61K31/138 ,  A61K31/16 ,  A61K31/19 ,  A61K31/20 ,  A61K31/277 ,  A61K31/341 ,  A61K31/343 ,  A61K31/36 ,  A61K31/37 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4365 ,  A61K31/4402 ,  A61K31/4418 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5365 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/551 ,  A61K31/57 ,  A61K31/575 ,  A61K31/661 ,  A61K38/39 ,  A61K45/06 ,  A61P21/00 ,  A61K2300/00

摘要： Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

公开(公告)号：US10028923B2

公开(公告)日：2018-07-24

申请号：US15339378

申请日：2016-10-31

申请人： Elcelyx Therapeutics, Inc.

发明人： Alain D. Baron ,  Mark S. Fineman ,  Nigel R. A. Beeley

IPC分类号： A61P3/10 ,  C07C279/26 ,  A61K9/22 ,  A61K31/155 ,  A61K45/06 ,  A61K31/55 ,  A61K31/137 ,  A61K31/357 ,  A61K31/485 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K31/155 ,  A61K9/00 ,  A61K9/0053 ,  A61K9/1623 ,  A61K9/20 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/2853 ,  A61K31/137 ,  A61K31/341 ,  A61K31/343 ,  A61K31/357 ,  A61K31/36 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4196 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/485 ,  A61K31/53 ,  A61K31/55 ,  A61K45/06 ,  C07C279/26 ,  C07D207/06 ,  C07D207/34 ,  C07D211/14 ,  C07D249/14 ,  C07D251/10 ,  C07D251/18 ,  C07D255/02 ,  C07D307/52 ,  C07D307/66 ,  C07D317/58 ,  C07D401/04 ,  C07D405/12 ,  C07D409/12

摘要： Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

公开(公告)号：US20180201608A1

公开(公告)日：2018-07-19

申请号：US15786772

申请日：2017-10-18

申请人： Azevan Pharmaceuticals, Inc.

发明人： Michael J. BROWNSTEIN

IPC分类号： C07D413/04 ,  A61K31/4025 ,  A61K31/397 ,  A61K31/422 ,  C07D413/14 ,  A61K31/4178 ,  A61K31/4453 ,  A61K31/496 ,  A61K45/00

CPC分类号： C07D413/04 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/4453 ,  A61K31/496 ,  A61K45/00 ,  A61P25/28 ,  C07D413/14

摘要： Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.